PubMed
Cerebrolysin for acute ischemic stroke (review)
Chen et al., 2017
Neurological & CognitiveIntl. ApprovedB
Cerebrolysin
FPE 1070
Cerebrolysin (FPE 1070) is a porcine brain-derived neuropeptide preparation containing a mixture of neurotrophic peptide fractions including BDNF-, NGF-, CNTF-, and GDNF-like fragments (<10kDa). Approved in Austria, Russia, China, South Korea, and other countries for Alzheimer's disease, post-stroke recovery, and traumatic brain injury. Multiple randomized controlled trials have demonstrated cognitive and functional improvements. Not FDA-approved in the US.
Observational report only — live community data. Not medical advice. Does not recommend doses, protocols, or treatments.
- Studies cited
- 5
- Research grade
- B
- Experience
- 100
- Activity
- 53
Overall check-ins
Trackers & reports
Overview
About Cerebrolysin
Cerebrolysin (FPE 1070) is a porcine brain-derived neuropeptide preparation containing a mixture of neurotrophic peptide fractions including BDNF-, NGF-, CNTF-, and GDNF-like fragments (<10kDa). Approved in Austria, Russia, China, South Korea, and other countries for Alzheimer's disease, post-stroke recovery, and traumatic brain injury. Multiple randomized controlled trials have demonstrated cognitive and functional improvements. Not FDA-approved in the US.
- Category
- Neurological & Cognitive
- Regulatory status
- Intl. Approved
- Also known as
- FPE 1070
- Self-reports
- 6
Community
What 6 users report
6 community reports
Overall experience
From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Favorable 100% · Mixed 0% · Unfavorable overall 0%
Most reported benefits
Benefits users selected when logging a favorable or mixed check-in.
Cognition
6
Self-reported dose per injection
Median bucket: 0–25 mcg · Most common: 0–25 mcg
Reports span 0–50 mcg
0–25
4
25–50
2
Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.
Commonly stacked with
Research
Cited research (3)
Source
PubMed
Cerebrolysin for acute ischaemic stroke
Ziganshina et al., 2023
PubMed
Cerebrolysin for acute ischaemic stroke
Ziganshina et al., 2017
Tools
Explore more
Explore
More ways to learn about Cerebrolysin from observational PeptIQ data.
Compare with
Related peptides
Help
Frequently asked
What do PeptIQ users report about Cerebrolysin?
This page summarizes 6 anonymized self-reports from PeptIQ users who track Cerebrolysin, including commonly reported effects and co-tracked peptides. These are observational patterns, not clinical outcomes.
How do side effects relate to overall experience for Cerebrolysin?
PeptIQ separates overall check-in ratings (favorable, mixed, or unfavorable) from logged side effects like nausea or fatigue. Users often report benefits and side effects in the same check-in — a high experience score does not mean zero side effects were noted.
What research is cited for Cerebrolysin?
3 sources are linked on this page, including PubMed articles, clinical trial registries, and FDA labels where applicable. Citations describe published research — not recommendations.
Is Cerebrolysin safe to use?
This wiki does not assess safety or recommend use. Cerebrolysin is listed as Intl. Approved. Consult a licensed clinician for personal medical decisions.
What are the purported benefits and uses of Cerebrolysin?
Research, primarily in animal models, suggests Cerebrolysin may have a wide range of therapeutic potentials due to its ability to promote angiogenesis (formation of new blood vessels), stimulate collagen synthesis, and modulate inflammatory responses.
SourceWhat is the legal status of Cerebrolysin?
Cerebrolysin is not approved by the FDA for any human use. There is no legal basis for selling it as a drug, food, or dietary supplement in the United States. The FDA has classified Cerebrolysin as a Category 2 bulk drug substance, which explicitly prohibits licensed compounding pharmacies from using it in compounded medications.
SourceWhat are the known or theoretical side effects and risks of Cerebrolysin?
The safety and effectiveness of Cerebrolysin have not been thoroughly evaluated in humans through rigorous clinical trials. This lack of human data means that safe dosages, short-term side effects, and long-term health consequences are largely unknown.
SourceWhat is the current state of research on Cerebrolysin?
While there are over 200 published studies on Cerebrolysin, the vast majority are animal or in vitro (cell) studies. These preclinical studies consistently show positive results across various tissue types. However, there is a significant lack of comprehensive human clinical trial data.
Source